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Human maternal autoantibodies can trigger autoimmune diseases such as congenital heart
block (CHB) in the progeny of women with lupus or Sjogren’s disease. The pathogenic
effect of early autoantibody (autoAb) exposure has been investigated in a murine neonatal
autoimmune ovarian disease (nAOD) model triggered by a unique ZP3 antibody. Although
immune complexes (IC) are formed in adult and neonatal ovaries, ZP3 antibody triggers
severe nAOD only in <7-day-old neonatal mice. Propensity to nAOD is due to the uniquely
hyper-responsive neonatal natural killer (NK) cells that lack the inhibitory Ly49C/I receptors.
In nAOD, the neonatal NK cells directly mediate ovarian inflammation and oocyte deple-
tion while simultaneously promoting de novo pathogenic ovarian-specificT cell responses.
Resistance to nAOD in older mice results from the emergence of the Ly49C/I+ NK cells that
regulate effector NK cells and from CD25+ regulatoryT cell control. In preliminary studies,
FcγRIII+ NK cells as well as the ovarian resident FcγRIII+ macrophages and/or dendritic
cells were found to be as indispensable players. Activated by ovarian IC, they migrate to
lymphoid organs where NK cell priming occurs. Remarkably, the findings in nAOD are very
similar to those reported for neonatal responses to a retrovirus and its cognate antibody that
lead to long-lasting immunity. Studies on nAOD therefore provide insights into maternal
autoAb-mediated neonatal autoimmunity, including CHB, while simultaneously uncovering
new properties of the neonatal innate and adaptive responses, lethality of premature infant
infection, and novel neonatal antiviral vaccine design.
Keywords: NK cells, Ly49 receptors, neonatal immunology, immune complex, autoimmune ovarian disease,
regulatoryT cells, congenital heart block, neonatal viral immunity
HUMAN NEONATAL AUTOIMMUNE DISEASE INDUCTION BY
MATERNAL AUTOANTIBODY EXEMPLIFIES NEONATAL
PROPENSITY TO AUTOIMMUNITY
Increased susceptibility of premature human infants and neona-
tal mice to infections is well-known (1). What is less appreciated
is that neonatal mice are also more susceptible to autoimmune
disease. For example, spontaneous autoimmune diseases occur in
mice thymectomized between days 1 and 4 but not after day 7 of
life (2). Autoimmune diseases induced by tissue antigen or pep-
tide immunization require complete Freund’s adjuvant (CFA) in
adult but not in neonatal mice (3–6). Indeed, neonatal female mice
immunized with an auto-peptide from the gender-specific ovar-
ian zona pellucida 3 (pZP3) antigen, mounted peptide-specific T
cell responses, and developed autoimmune ovarian disease (AOD)
in 3 weeks. In contrast, the same ZP3 peptide induced tolerance
in neonatal male mice as a foreign antigen (4). The opposing
responses to self and foreign antigens in the neonates suggest that
the neonatal tolerance paradigm (7, 8) should be revisited because
it is built mainly on responses to foreign antigens or peptides
including alloantigen (9–15). Indeed, in contrast to the neona-
tal tolerance paradigm, newborn mice responded as efficiently
as adult mice to viral, nominal, and autoantigen, when the anti-
gen dose, injection site, and adjuvant type were adjusted (16–18).
Finally, neonatal propensity to autoimmunity is supported by the
induction of fetal or neonatal self-tissue damage after the transpla-
cental transfer of maternal autoantibody (autoAb) that often does
not harm the adult.
Autoimmune disease occurs preferentially in women of repro-
ductive age, and circulating autoAb is a hallmark of autoimmunity.
The finding of neonatal autoimmune disease caused by maternal
autoAb establishes its pathogenic potential. The impact of mater-
nal autoAb is often transient, and neonates recover as antibody
level declines. However, in some cases, maternal autoAb effects
persist and induce permanent tissue damage. An example is con-
genital heart block (CHB) that occurs in the fetuses or infants
of women with systemic lupus erythrematosus (SLE) or Sjogren’s
disease. Although CHB has many possible etiologies (19), a strong
candidate is the transplacental transfer of maternal autoAb against
the ribonucleoproteins SSA/Ro and SSB/La (20), with SSB/La hav-
ing a stronger association (21). The maternal autoAb damages
the atrioventricular node of the cardiac conduction system by an
unknown mechanism. Likely, CHB pathogenesis involves excessive
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apoptosis of cardiomyocytes, tissue inflammation and fibrosis, and
the interaction of macrophages and fibroblasts (21). The clinical
impact of CHB is significant. Although about 2% of neonates from
mothers with autoAb to SSA/Ro and SSB/La develop CHB (20),
the recurrence rate for an autoAb-positive mother with a pre-
viously affected child is 16–18% (22). Importantly, complete or
third degree CHB is irreversible with a mortality rate of 12–43%
(22). Although first or second degree heart block may reverse with
treatment, most children require permanent pacemakers (22).
Maternal autoAb can induce neonatal autoimmune diseases
other than CHB. Neonatal myasthenia gravis, associated with
severe deformity and difficult deliveries, is caused by maternal
autoAb to the fetal form of acetylcholine receptor and a muscle-
specific kinase (23, 24). Neonatal Graves’ disease involves agonist
autoAb targeting the thyroid stimulating hormone receptor (19).
Neonatal pemphigus is mediated by autoAb to the desmoglein-1
or 3 antigens (25, 26). Several studies have shown a positive corre-
lation between anti-phospholipid or lupus anticoagulant autoAb,
present in patients with SLE or anti-phospholipid syndrome, and
a high risk of premature onset of labor, low birth weight and
early miscarriages of their progeny (19, 27). In addition, neuronal
apoptosis and subsequent abortion are consequences of mater-
nal autoAb to DNA in SLE patients (28); and autism spectrum
disorders are linked to maternal autoAb against fetal brain anti-
gens (29, 30). The mechanism of human neonatal autoimmunity
is currently uncertain, and we have used the neonatal autoim-
mune ovarian disease (nAOD) model to address the questions of
why neonates are more susceptible to autoimmune disease, and
how maternal autoAb induce the tissue damage. Below, we have
described some of the characteristics and advantages of nAOD
that make it a very useful model.
In addition to its ability to cause tissue injury and disease, anti-
body has been found to elicit changes in neonatal or very young
mice and promote subsequent full-blown autoimmune diseases.
An example of the “pre-disease” state is the pre-diabetes that pre-
cedes clinical diabetes by months to years (31–34). In NOD mice,
a very early cascade of cellular and cytokine responses to local
immune complexes (IC) in pancreatic islets was found to cause
subsequent development of pathogenic T cell responses and clini-
cal juvenile diabetes (35). In addition, maternal autoAb directed to
islet antigens was reported as a requirement for type I diabetes in
the NOD mice (36) or to accelerate diabetes onset in a transgenic
mouse model (37).
Therefore, maternal autoAb can induce either transient pathol-
ogy or more persistent tissue damage in the progeny. It may also
condition the fetus/infant early in life for a late onset autoimmune
disease. In these situations, the design of novel preventive thera-
pies will necessitate a thorough understanding of the pathogenic
autoimmune response in the very young individuals, including
their innate and adaptive neonatal responses to IC created by
autoAb.
NEONATAL AUTOIMMUNE OVARIAN DISEASE MODEL AND
ITS UNIQUE FEATURES
The aforementioned findings indicate that newborns are simul-
taneously more susceptible to infections and to autoimmunity.
While“immaturity”of the neonatal immune system might explain
the increased sensitivity to pathogens, it is not immediately appar-
ent why newborns are more susceptible to autoimmune disease.
A potential explanation is that the maturing neonatal immune
system is less stringently regulated relative to the adults. Thus,
an overactive neonatal response would induce both autoimmune
disease and severe post-infection immunopathology, including
sepsis. While other authors support the latter (38), our study
focuses on the questions of why newborns are more susceptible
to nAOD and how nAOD is induced. We have summarized our
results in this review.
Autoimmune ovarian disease is a known cause of primary or
secondary premature ovarian failure that can lead to infertility
of pubertal and adult women (39, 40). Because ovarian dysfunc-
tion is not generally manifested until puberty, it cannot be certain
that primary AOD, like type I diabetes, is preceded by a “pre-
disease” exemplified by nAOD. While the clinical relevance of
nAOD remains unresolved, the murine nAOD model itself has
proven to be an excellent platform for investigating the role of the
neonatal immune response to autoantigen and the role of autoAb
in autoimmune disease pathogenesis.
ZP3 is a major sperm receptor in fertilization (41). The pZP3
(330–342) contains a pathogenic T cell epitope and a native B cell
epitope 335–342 (42), and antibodies to this pZP3 B cell epitope
inhibit sperm binding to the zona pellucida (41, 43). Adult mice
immunized with pZP3 in CFA develop a pathogenic CD4+ T cell
response and a non-pathogenic antibody response. The latter was
confirmed in adult mice immunized with a chimeric ZP3 peptide
that contains the native B cell epitope 335–342 linked to a foreign
T cell peptide from the bovine RNAse (43). The mice produce ZP3
antibodies that bind to the ovarian zona pellucida without causing
ovarian pathology. However, 70% of the females immunized with
the chimeric ZP3 peptide were infertile because of the contracep-
tive effect of ZP3 antibodies. In the remnant fertile females, the
maternal ZP3 autoAb transferred to the neonates induced severe
nAOD (Figure 1). Remarkably, nAOD developed in the progeny
only when the ZP3 antibody exposure was initiated within the first
6 days of life, as documented by feeding antibody-positive milk to
normal pups of different ages, and by antibody transfer (44).
Neonatal autoimmune ovarian disease is a unique and versa-
tile model. First, ovaries can be safely removed to deplete ovarian
autoantigens; and ovaries from donors of different ages and with
different genetic modifications can be implanted under the kidney
capsule can be used to monitor the effect of putative molecules
in nAOD development. This approach has allowed us to show
that nAOD susceptibility is not related to the intrinsic differences
between adult and neonatal ovaries (44). It has also allowed us to
find, unexpectedly, that nAOD induction requires resident ovar-
ian cells that express FcγRIII. Second, nAOD induced by maternal
immunization with the novel ZP3 chimeric peptide induces ZP3
antibodies without concomitant pathogenic T cell response. In
addition to feeding pups with ZP3 antibody-positive mothers,
nAOD is also inducible by passive transfer of a monoclonal anti-
body that recognizes the pZP3 335–342 (45). This allowed us to
adjust the antibody dose to body weight between neonatal or adult
mice and show that the nAOD resistance of adult mice is not
related to insufficient antibody or ovarian IC. Third, there has
been uncertainties regarding the physiological relevance of the
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FIGURE 1 | Ovarian immunopathology ofTI-nAOD in C57BL/6 Rag1−/−
mice injected with pZP3 monoclonal antibody (mAb) in the first week
of life. (A) Ovarian atrophy with major oocyte depletion and disrupted
ovarian architecture. (B) Normal ovarian histology in mice injected with ZP3
mAb and NK cell-depleting (NK1.1) mAb. (C–E) Mononuclear cell-dominant
(C, arrows), or granulocyte-dominant (E, arrows) infiltrates inside ovarian
follicles is a common feature of ovarian pathology in TI-nAOD. The dotted
lines (C,E) outline ovarian follicles where oocytes are replaced by
inflammatory cells while the asterisks (C–E) indicate normal ovarian follicles.
(D), Inflammatory cells also infiltrate the ovarian interstitium (arrows). In
(F), Immunofluorescence detection of mouse IgG (green fluorescence
represents zona pellucida-bound ZP3 mAb); and NKG2D+ NK cells (red
fluorescence) detectable outside and inside the zona pellucida (white
arrows). DAPI (nuclear blue staining). Magnification [(A,B): 50×;
(C–F): 400×]. Hematolyxin and eosin stain (A–E). [Reproduced from Rival
et al. (45), J. Immunol. 191, 2865–2869].
ZP3 auto-peptide and its cognate antibody because (1) pZP3 was
arbitrarily chosen as a novel auto-peptide with T and B cell epi-
topes; and (2) AOD induction also requires immunization with
adjuvants. However, regulatory T cell (Treg) depletion from nor-
mal female mice leads to spontaneous production of autoAb that
targets the same ZP3 335–342 epitope and the transfer of the sera
from these animals induces nAOD in naïve pups. Thus, the pZP3
that has been studied for over 20 years is, in fact, a physiologically
relevant B cell autoepitope. Fourth, nAOD develops in wild-type
mice, and interestingly, nAOD also develops in mice that lack T and
B cells. We call them T cell-dependent nAOD (TD-nAOD) model
and T cell-independent nAOD (TI-nAOD) model, respectively.
TD-nAOD induction is MHC-restricted, and it provides a use-
ful platform for studying neonatal innate and adaptive responses
and their interaction. On the other hand, the study of TI-nAOD
in the recombination activation gene (Rag) knock out (KO) mice
allows a reductionist approach to critically dissect the neonatal
innate response. For example, we can define the novel properties
of neonatal natural killer (NK) cells in vivo without the complex
interaction between the innate and adaptive immune cells.
With the two nAOD models, we have addressed two funda-
mental questions on neonatal autoimmune disease: (1) Why are
neonates more susceptible to autoimmunity; and (2) How do
maternal autoAb induce an autoimmune disease in neonatal mice?
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WHY ARE NEONATES MORE SUSCEPTIBLE TO nAOD?
The neonatal time window of nAOD induction applies equally to
TD-nAOD and TI-nAOD. Therefore, neonatal innate responses
are sufficient to confer propensity to nAOD in newborn mice (44,
45). NK cells are components of the innate response that can per-
form antibody-dependent cellular cytotoxicity (ADCC) through
FcγRIII and produce multiple cytokines. Differences in the phe-
notype and function of neonatal and adult NK cells have been
described (46). However, while some reports show a poor neonatal
NK cell function compared to adults, others demonstrate equal or
enhanced effector functions in neonatal NK cells. Our recent work
has convincingly demonstrated that neonatal NK cells and their
unique properties are the key explanation for newborn propen-
sity to nAOD (45). Strikingly, the age of the donors of NK cells
that restore nAOD in genetically NK cell-deficient recipients that
lack the rag and the common gamma chain genes, correlated pre-
cisely with the neonatal time window for nAOD induction. Thus,
neonatal NK cells are critical for nAOD susceptibility (45). NK
cell activation depends on the balance of signaling through stim-
ulatory and inhibitory receptors (47). Self-tolerance by NK cells is
achieved by the interaction of major histocompatibility complex
class I (MHC I) with the murine Ly49 receptors or the human killer
cell Ig-like receptors (KIR). However, expression of these receptors
is stochastic. Those NK cells that lack receptors for self-MHC I are
potentially autoreactive. However, in a process termed licensing,
the NK cells that do not recognize self-MHC I become “anergic,”
thus ensuring self-tolerance (48). Strikingly, it has been recently
shown that the “anergic” NK cells that do not recognize self can
become activated during inflammatory conditions and are more
efficient in clearing infections or tumor cells than the licensed NK
cells (49–51).
The expression of Ly49 receptors is known to be ontogenetically
regulated; while ~5% of NK cells express Ly49C/I receptors in the
first week of life, the frequency in adult mice is 10 times higher (52–
54). This prompted us to investigate the role of Ly49 receptors in
nAOD induction, and to address whether the delayed expression of
Ly49C/I on NK cells confers adult resistance to nAOD. In a pivotal
experiment, we showed that adult Ly49C/I negative NK cells could
also induce nAOD only after the Ly49C/I+ NK cell subpopula-
tion has been depleted in vivo. Our findings made three important
points: (1) neonatal NK cells are documented for the first time to
be functional and they are, in fact, hyper-reactive, (2) both neona-
tal and adult Ly49C/I negative NK cells can induce nAOD, and
(3) they raise the interesting possibility that adult Ly49C/I+ NK
cells can inhibit the activation of Ly49C/I negative NK cells, as
shown by their capacity to block nAOD induction. Our findings
are supported by recent literature on NK cells. Ivarsson et al. (55)
recently showed that human fetal NK cells are hyper-responsive to
cytokine stimulation, and CD16 engagement can overcome their
hypo-responsiveness in killing HLA-negative targets. This study
provided a clinical correlate to our findings. In addition, it has
been shown that Ly49-negative NK cells can acquire full effector
functions under inflammatory conditions. We should emphasize
that whereas previous work (49, 51) has described intrinsic NK
cell regulation, our study on nAOD provides the first evidence of
extrinsic NK cell inhibition, where Ly49C/I+ NK cells may inhibit
Ly49C/I negative NK cells (Figure 2). However, this possibility
FIGURE 2 | Mechanism of nAOD induction. Ovarian ZP3 immune
complexes on the zona pellucida (ZP, green) are formed after maternal
autoAb transfer and stimulate FcγRIII+ macrophage/dendritic cells that
activate (1) a de novo CD4+ T cell response (in red), and (2) Ly49-negative
neonatal NK cells (in blue). These NK cells produce IFNγ promoting a Th1
pathogenic CD4+ T cell response to ovarian antigens. Ovarian inflammation
and oocyte depletion is, in turn, mediated by the FcγRIII+ neonatal NK cells
and activated Th1 effector CD4+ T cells. Mice older than 9 days fail to
develop nAOD because of the emergence of Ly49+ NK cells (in purple
dotted box) and Treg function (not depicted).
still requires further investigation. We currently speculate an indi-
rect regulation that depends on the competition between the two
NK cell subsets for the interaction with dendritic cells, which are
required for NK cell priming (56, 57).
As a mechanism of nAOD resistance in mice older than 7 days,
Treg were documented to control susceptibility to nAOD. Thus,
when Treg were depleted from 9-day-old pups with CD25 anti-
body, the neonatal time window was extended and the older mice
became fully susceptible to nAOD (44). Therefore, at least two
mechanisms acquired by adult mice confer resistance to autoim-
mune disease: (1) the innate system, by restraining NK cell activa-
tion with the acquisition of the inhibitory Ly49 receptors, and (2)
the adaptive system, by acquiring Treg function. In contrast, these
mechanisms are deficient in the neonatal mouse.
HOW DO THE MATERNAL ZP3 autoAb CAUSE OVARIAN
INJURY?
DUAL NK CELL REQUIREMENTS IN nAOD: INDUCTION OF
ANTIBODY-DEPENDENT CYTOTOXICITY (ADCC) AND OVARIAN
ANTIGEN-SPECIFIC PATHOGENIC CD4 T CELL RESPONSE
Maternal ZP3 autoAb transferred through the milk but not the
placenta was critical for nAOD induction (44). Within 24 h, ZP3
IC was detectable in the zona pellucida of the ovary, a process
that culminated in significant ovarian inflammation and loss of
oocytes over the next 2 weeks [Figure 1; Ref. (44)]. The IC can
cause immunopathology by: (1) activation of the complement
cascade, (2) FcγRIII-dependent ADCC, and (3) T cell activation
mediated by FcγRIII and/or complement receptor-bearing antigen
presenting cells (APC). Complement C3b and C5b were unde-
tectable in ovaries of mice with nAOD. However, studies with
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blocking antibodies and gene KO mice indicated that nAOD is
dependent on FcγRIII expression (44, 58). In fact, we found that
TD-nAOD pathogenesis requires both FcγRIII-dependent ADCC
and a de novo T cell response. First, the neonatal NK cell must
express FcγRIII to support nAOD (58). Second, the critical CD4+
T cells are required in TD-nAOD because (1) T cell depletion
prevents nAOD, (2) CD4+ T cells from mice with nAOD trans-
fer ovarian disease to naïve pups (44). Importantly, NK cells are
required in both the inductive phase and the effector phase of
the T cell response (58). Likely, the NK cell-derived IFNγ skews
the T cell response toward IFNγ-producing Th1 cells (Figure 2).
Indeed, IFNγ neutralization by antibody in the cell donors blocked
the adoptive transfer of nAOD (58) and IFNγ-deficient NK cells
failed to induce nAOD. Importantly, requirement of NK cells and
FcγRIII expression have also been documented in the adult model
of myasthenia gravis (59).
In our ongoing research, we have further clarified the patho-
genesis of nAOD by making the following observations. First,
in addition to NK cells, ovarian resident FcγRIII+ macrophages
and/or dendritic cells are requisites in TD-nAOD. Second, NK
cell activation most likely occurs in the lymph nodes where they
are primed by the ovarian-derived FcγRIII+ cells. Third, NK cell
homing and activation are dependent on IL-15, CD70 and CD27,
and CXCR3.
ANTIBODY TO VIRAL ANTIGEN ALSO CO-STIMULATES
ACTIVE IMMUNITY TO VIRUS IN NEONATAL BUT NOT ADULT
MICE
Maternal anti-microbial antibodies confer transient protection
from infection to the progeny. However, compelling studies have
shown that co-injection of a small amount of antiviral antibody
with a live virus in neonatal mice can evoke effective long-
term immunity against the virus. Neonatal infection with the
FrCasE murine retrovirus before day 5–6 after birth leads to a
virus-specific Treg response that inhibits efficient antiviral immu-
nity (60). This results in fatality from neurodegeneration within
2 months and from erythroleukemia within 4–5 months. However,
the Treg response is dramatically curtailed when the virus-infected
neonatal mice receive a small dose of epitope-specific antiviral
antibody within 2 days after the viral infection (61, 62). Concomi-
tantly, the mice develop a strong antivirus CD8+ T cell response
and life-long protection against the virus. As will be described
below, the underlying mechanisms behind this successful neonatal
antiviral vaccination schema are remarkably similar to the mech-
anism involved in nAOD induction. Therefore, neonatal exposure
to antibody can enhance immunity against both autologous and
foreign antigens.
COMMONMECHANISMS ARE SHARED BETWEEN
AUTOIMMUNITY AND VIRAL IMMUNITY INDUCTION BY
NEONATAL IMMUNE COMPLEXES
It is remarkable that neonatal IC formation by an epitope-specific
antibody can lead to both autoimmune disease and antiviral
immunity. Even more striking is the fact that the two responses
deploy very similar mechanisms. They both require: (1) antibody
injection and IC formation within the first week of life, (2) epitope-
specific antibody that targets the functional domain of the antigen,
(3) NK cells, (4) FcγRIII, (5) de novo induction of T cell responses,
and (6) IFNγ. In both cases, the responses to IC beyond the neona-
tal time window were inhibited by Treg. Based on findings from
our recent nAOD study, we can now add to this list, the critical
influence of NK cell expression of the Ly49 inhibitory receptors.
GENERAL CONCLUSION/SUMMARY
It is generally accepted that the higher susceptibility of newborns
to infections is a consequence of the immature neonatal immune
system. In support of this concept, many studies have described
a weaker response by the neonatal immune system. However, this
concept is still controversial, as others have found an equiva-
lent or even stronger neonatal immune responses over the adult
response. Moreover, a recent study showed that the poor protec-
tion to respiratory syncytial virus infection in newborns is due
to the inhibition of the antibody production by the IFNγ pro-
duced by neonatal NK cells and T cells (63), suggesting that the
neonatal immune system involves a complex cellular and molecu-
lar interplay. Experimental data derived from nAOD research have
added new insight on the in vivo responsiveness of the newborn
immune system. They clearly indicated that neonatal mice have the
capacity to mount a robust immune response to tissue-associated
IC that surpasses an adult response. The primary mechanism is
the lower threshold of neonatal NK cell responses to tissue IC;
and the capacity of neonatal NK cells to promote a pathogenic
neonatal T cell response. It is important to emphasize that recent
studies on human NK cells in support of this concept are also
emerging (55). Our findings on nAOD are concordant with the
observations by Michaud et al. (61) and Nasser et al. (60, 62) on
the neonatal response to a foreign antigen in the context of a viral
infection in the newborn. In both, the antibody exposure restricted
to the first few days of life has been clearly documented to strongly
enhance the neonatal immune response against its cognate anti-
gen. The mechanisms shared between these two models should
support a novel approach in effective vaccine design for the very
young.
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